Imagion Biosystems Ltd. (AU:IBX) has released an update.
Imagion Biosystems Ltd. has successfully secured A$3 million in a capital raising effort to speed up clinical studies and development of its MagSense® platform technology for cancer diagnosis. The company will issue 150 million new shares and 75 million options to investors, with a first tranche expected to be issued on 16 October 2024. This funding will enable the advancement of Imagion Biosystems’ clinical programs targeting various cancers, with key clinical milestones anticipated in 2025.
For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.